Danielle Showalter

Danielle Showalter advises clients on reimbursement, policy, and market access strategies for diagnostic, medical device, and pharmaceutical companies.

Danielle provides a rich background in consulting and research services, particularly in the areas of physician payment, CPT® coding, device reimbursement strategies, and diagnostic payment policy.

Prior to Avalere, Danielle was the director of Health Policy and Reimbursement at ADVI, assisting diagnostic and device clients in developing and implementing coding, coverage, and reimbursement strategies as well as understanding the impact of regulatory and legislative changes. Danielle also worked for Altarum Institute, providing research support, expertise, and primary IRB review for TRICARE.

Danielle has an MA in public health from the George Washington University and a BA from the University of Virginia.

Authored Content

While precision medicine is expected to revolutionize patient therapy, the increasing complexity of diagnostics is leading policymakers to revamp the way these tests are regulated and paid for.

Last Tuesday, August 2, the Centers for Medicare & Medicaid Services (CMS) released the FY 2017 IPPS final rule